51439-89-5

Upstream product

• 96306-54-6 <3-methoxy-4-(phenylmethoxy)phenyl>phenylmethane 
• 4421-08-3 3-methoxy-4-hydroxybenzonitrile 
• 100-58-3 phenylmagnesium bromide 
• 121-33-5 vanillin 
• 92495-78-8 4-benzyl-2-methoxyphenol 
• 2426-87-1 3-methoxy-4-(phenylmethoxy)benzaldehyde 
• 55252-36-3 4-(4-hydroxy-3-methoxy-benzhydrylidene)-2-methoxy-cyclohexa-2,5-dienone 
• 96306-72-8 (4-Benzyloxy-3-methoxy-phenyl)-phenyl-methanol 
• 90-05-1 2-methoxy-phenol 
• 65-85-0 benzoic acid 

Downstream Products

• 92495-78-8 4-benzyl-2-methoxyphenol 
• 88857-58-3 [4-(2-Bromo-ethoxy)-3-methoxy-phenyl]-phenyl-methanone 
• 133455-09-1 1-[4-(3-bromopropoxy)-3-methoxyphenyl]phenylmethanone 
• 75177-11-6 <(5-benzoyl-2-hydroxy-3-methoxybenzyl)imino>bisacetic acid 
• 926291-91-0 4-cetyloxy-3-methoxybenzophenone 
• 926291-92-1 4-octyloxy-3-methoxybenzophenone 
• 926291-93-2 4-butyloxy-3-methoxybenzophenone 
• 383382-97-6 1-(4-acetyloxy-3-methoxyphenyl)-1-phenylmethanone 
• 400870-98-6 (4-hydroxy-3-methoxy-5-nitro-phenyl)-phenyl-methanone 
• 179018-65-6 [3-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-phenyl-methanone 
• 179019-09-1 [3-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-phenyl-methanol 
• 383382-96-5 1-(4-acetyloxy-3-methoxy-2-nitrophenyl)-1-phenylmethanone 
• 383382-84-1 1-(3,4-dihydroxy-2-nitrophenyl)-1-phenylmethanone 
• 383382-98-7 (4-Hydroxy-3-methoxy-2-nitro-phenyl)-phenyl-methanone 

Relevant academic research and scientific papers

Natural-Product-Inspired Compounds as Countermeasures against the Liver Carcinogen Aflatoxin B1

Aflatoxin B1 (AfB1) ranks among the most potent liver carcinogens known, and the accidental or intentional exposure of humans and livestock to this toxin remains a serious global threat. One protective measure that had been proposed is employing small-molecule therapeutics capable of mitigating the toxicity of AfB1; however, to date, these efforts have had little clinical success. To identify molecular scaffolds that reduce the toxicity of AfB1, we developed a cell-based high-throughput high-content imaging assay that enabled our team to test natural products (pure compounds, fractions, and extracts) for protection of monolayers and spheroids composed of HepG2 liver cells against AfB1. The spheroid assay showed notable potential for further development, as it afforded greater sensitivity of HepG2 cells to AfB1, which is believed to better mimic the in vivo response of hepatocytes to the toxin. One of the most bioactive compounds to arise from this investigation was alternariol-9-methyl ether (1, purified from an Alternaria sp. isolate), which inspired the synthesis and testing of several structurally related molecules. Based on these findings, it is proposed that several types of natural and synthetic polyarene molecules that have undergone oxidative functionalization (e.g., compounds containing 3-methoxyphenol moieties) are promising starting points for the development of new agents that protect against AfB1 toxicity.

An eco-friendly Co(OAc)2-catalyzed aerobic oxidation of 4-benzylphenols into 4-hydroxybenzophenones

An undecorated Co(OAc)2-catalyzed aerobic oxidation system has been reported that enables direct transformation of 4-benzylphenols into the corresponding 4-hydroxybenzophenones. The procedure is especially suitable for electron-withdrawing group-containing substrates, which are commonly inefficient to conduct this category of oxidation. Based on well-defined p-benzoquinone methides and the confirmed ethereal intermediate, a plausible mechanism was depicted.

Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase

A homologous series of novel nitro-catechol structures (7a-7e) were synthesized and tested as inhibitors of the enzyme catechol-O-methyltransferase (COMT). Increasing chain length was found to have significant impact on both brain penetration and duration

LTA4 Hydrolase inhibitors

The present invention provides compounds of the formula Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof wherein Ar1 and Ar2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB4 production, such as proriasis, ulcerative colitis, IBD and asthma.

Structure-activity relationship studies on 1-[2-(4- phenylphenoxy)ethyl]pyrrolidine (SC-22716), a potent inhibitor of leukotriene A4 (LTA4) hydrolase

Leukotriene B4 (LTB4) is a pro-inflammatory mediator that has been implicated in the pathogenesis of a number of diseases including inflammatory bowel disease (IBD) and psoriasis. Since the action of LTA4 hydrolase is the rate-limiting step for LTB4 production, this enzyme represents an attractive pharmacological target for the suppression of LTB4 production. From an in- house screening program, SC-22716 (1, 1-[2-(4- phenylphenoxy)ethyl]pyrrolidine) was identified as a potent inhibitor of LTA4 hydrolase. Structure-activity relationship (SAR) studies around this structural class resulted in the identification of a number of novel, potent inhibitors of LTA4 hydrolase, several of which demonstrated good oral activity in a mouse ex vivo whole blood assay.